Capricor Therapeutics reports Q2 2026 results with deramiocel focus amid FDA advisory committee developments
Capricor Therapeutics reported Q2 2026 results and a corporate update, maintaining focus on deramiocel for Duchenne muscular dystrophy, with recent FDA advisory committee developments shaping investor expectations. Multiple market participants discussed the earnings and FDA-related developments around the same time.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@TU_Crypto_News
Capricor Therapeutics reported Q2 2026 results and a corporate update, keeping focus on deramiocel for Duchenne muscular dystrophy as recent FDA advisory committee developments shape investor expectations.
@GlenChristy6
$CAPR Hopefully higher ups at the FDA will be more rational than the circus animals they sent to the Adcom and approve this much needed drug. To not would go against their mandate and put the lives of young adults in danger and possibly death. Do the right thing @FDA
@hassytrades
Watchlist into tomorrow $CAPR -> earnings were strong; key level $7.5 and we see $8/8.5+ $XHG -> China name trying to push back to the upside; we need over $4.5, and we should get going to $5/6+ $ONFO -> nice move into after-hours; has the ability for explosive runs;
@seedy19tron
lol $capr longs you do not get to twerk on todays price action! https://t.co/FVz2DlhCCw